You are here

Treating CML

Anything relating to the treatment and therapy available for CML

Post count: 
2 866
Thread count: 
417
Machine name: 
treating_cml

Diagnosing, Testing, and Monitoring Chronic Myeloid Leukaemia: A guide for patients

David Fitz's picture
Submitted by David Fitz on Wed, 06/12/2017 - 2:56pm

This booklet provides an overview of the quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) test. It includes a description of the qRT-PCR International Standardisation (IS) project within the context of the recently updated (2013) ELNet Recommendations and NCCN Treatment Guidelines for the treatment and management of Ph+CML based on molecular testing by qRT-PCR. Click on the picture of the booklet cover below to open it.


Our Publications

David Fitz's picture
Submitted by David Fitz on Wed, 06/12/2017 - 2:42pm

CML Support publish booklets and leaflets to help people understand PH+CML.

Quantitative Reverse Transcription Polymerase Chain Reaction: A primer for patients 

This booklet provides an overview of the quantitative Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR) test. It includes a description of the qRT-PCR International Standardisation (IS) project within the context of the European Leukaemia Net Recommendations and NCCN Treatment Guidelines for the treatment and management of Ph+CML based on molecular testing by qRT-PCR.

Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia

Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

DASFREE

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response.

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response.

Bfore-

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pages